These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1190 related items for PubMed ID: 14532793

  • 1. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ.
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [Abstract] [Full Text] [Related]

  • 2. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 3. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Mar 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 4. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P, Katcher J, Levin H, Zippe C, Klein E.
    Urology; 1996 Aug 01; 48(2):249-60. PubMed ID: 8753737
    [Abstract] [Full Text] [Related]

  • 5. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.
    BJU Int; 2011 Jun 01; 107(11):1748-54. PubMed ID: 20883488
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK, Lee RJ, Snow G, Lee CM, Tward JD, Middleton AW, Middleton GW, Sause WT.
    Urology; 2007 Feb 01; 69(2):295-9. PubMed ID: 17320667
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ, Wieder JA, Jack GS, Dorey F, deKernion JB, Aronson WJ.
    J Urol; 2002 Jul 01; 168(1):110-5. PubMed ID: 12050502
    [Abstract] [Full Text] [Related]

  • 10. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K.
    J Clin Oncol; 2009 Jun 20; 27(18):2924-30. PubMed ID: 19433689
    [Abstract] [Full Text] [Related]

  • 11. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
    Swindle P, Eastham JA, Ohori M, Kattan MW, Wheeler T, Maru N, Slawin K, Scardino PT.
    J Urol; 2005 Sep 20; 174(3):903-7. PubMed ID: 16093984
    [Abstract] [Full Text] [Related]

  • 12. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.
    Cancer; 2002 Dec 01; 95(11):2302-7. PubMed ID: 12436435
    [Abstract] [Full Text] [Related]

  • 13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
    Delongchamps NB, Zerbib M, Mejean A, Rouach Y, Debre B, Peyromaure M.
    Can J Urol; 2009 Oct 01; 16(5):4813-9. PubMed ID: 19796456
    [Abstract] [Full Text] [Related]

  • 14. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes?
    King CR, Presti JC, Gill H, Brooks J, Hancock SL.
    Int J Radiat Oncol Biol Phys; 2004 Jun 01; 59(2):341-7. PubMed ID: 15145146
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J, Pahernik S, Tremmel T, Haferkamp A, Buse S, Hohenfellner M.
    BJU Int; 2008 Nov 01; 102(10):1413-8. PubMed ID: 18537951
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
    Blute ML, Bostwick DG, Bergstralh EJ, Slezak JM, Martin SK, Amling CL, Zincke H.
    Urology; 1997 Nov 01; 50(5):733-9. PubMed ID: 9372884
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.